Anti-CD25 [7D4]
Catalogue Number: AB02216-1.1-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | IL-2-RA; Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL2-RA; p55 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Mouse |
| Clone: | 7D4 |
| Isotype: | IgG1 |
| Immunogen: | The original rat IgM version of this antibody was raised by immunizing Lewis rats with HT2 cells in complete Freund's adjuvant via a intraperitoneal injection and subsequent generation of hybridomas. |
| Application: | FC, Depl |
Additional Text
Gene Name
IL2RA
Gene ID
16184
Uniprot ID
P01590
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
7D4 is a non-IL-2 blocking anti-CD25 antibody that has been widely used to identify CD25-positive cells via flow cytometry (Kohyama et al., 2012; pmid: 22399592), for instance, to analyse Lymph node cells from BALB/c mice that were untreated or treated with 0.25 mg PC61 (Onizuka et al., 1999; pmid: 10397255) or to characterize brain-infiltrating immune cells (Maes et al., 2013). Although 7D4 does not inhibit IL-2 binding itself, it shows synergistic qualities with a cancer vaccine; namely, 7D4 with a cancer vaccine boosted the vaccine-induced anti-tumour response. Furthermore, this antibody was shown to be able to induce inactivation of regulatory T cells (Treg); the effect was particularly significant when this clone was used synergistically with another anti-CD25 clone - PC61 (Ab01107) (Kohm et al., 2006; pmid: 16517695; McNeill et al., 2007; pmid: 17212768). 7D4, when turned into a mouse IgG2a format, exhibits depleting qualities against Treg cells and can be used to remove Treg lymphocytes from the tumoral environment without blocking CD25 (IL-2 pathway) on T effector cells (Solomon et al., 2020). As a result, it can be utilized as a potential immunotherapy agent achieving Treg depletion without T effector cells' debilitation (Solomon et al., 2020). Finally, it was demonstrated that such anti-CD25 non-IL-2 blocking antibodies are successful agents in promoting effector activation and leading to strong antitumor activity (Solomon et al., 2020).
Short Description
This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgM format, for improved compatibility with existing reagents, assays and techniques.
AB02216-1.1 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations